The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

Shuji Ichihara, Shinichi Toyooka, Yoshiro Fujiwara, Katsuyuki Hotta, Hisayuki Shigematsu, Masaki Tokumo, Junichi Sou, Hiroaki Asano, Kouichi Ichimura, Keisuke Aoe, Motoi Aoe, Katsuyuki Kiura, Kenji Shimizu, Hiroshi Date, Nobuyoshi Shimizu

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

We investigated the relationships between genetic factors and clinical outcome in Japanese non-small-cell lung cancer (NSCLC) patients treated with gefitinib. Ninety-eight NSCLC patients who had been treated with gefitinib, were screened for mutations in epidermal growth factor receptor (EGFR) exons 18-21, KRAS exon2, and polymorphisms including the CA simple sequence repeat in intronl (CA-SSR1) and single nucleotide polymorphisms in the promoter region (-216G/T and -191C/A), using a PCR-based assay and direct sequencing. The EGFR copy number status was also evaluated using a fluorescence in situ hybridization assay. EGFR and KRAS mutations were found in 38 (38.8%) and 8 (8.2%) of the 98 patients, respectively. A high EGFR copy number status was identified in 31 (41.3%) of the 75 assessable patients. Drug-sensitive EGFR mutations limited to exon19 deletions and L858R were independent predictive factors of a stronger sensitivity to gefitinib (p = 0.0002), the overall survival (OS) (p = 0.0036), and prolonged progression-free survival (PFS) (p <0.0001). The EGFR copy number status was not related to a sensitivity to gefitinib and prolonged OS and PFS. Regarding polymorphisms, patients with a short CA-SSR1 showed a prolonged OS as compared with those with a long length in patients with a drug-sensitive EGFR mutation, although this difference was not significant (p = 0.13). Thus, drug-sensitive EGFR mutations predict a favorable clinical outcome and a high EGFR copy number may not be related to clinical benefits in gefitinib-treated Japanese patients with NSCLC. Our findings also suggest that the CA-SSR1 length may influence the clinical outcome in patients with a drug-sensitive EGFR mutation.

Original languageEnglish
Pages (from-to)1239-1247
Number of pages9
JournalInternational Journal of Cancer
Volume120
Issue number6
DOIs
Publication statusPublished - Mar 15 2007

Fingerprint

erbB-1 Genes
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Pharmaceutical Preparations
Disease-Free Survival
Survival
gefitinib
Fluorescence In Situ Hybridization
Genetic Promoter Regions
Microsatellite Repeats
Single Nucleotide Polymorphism
Exons

Keywords

  • Amplification
  • EGFR
  • Gefitinib
  • Mutation
  • NSCLC
  • Polymorphism

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. / Ichihara, Shuji; Toyooka, Shinichi; Fujiwara, Yoshiro; Hotta, Katsuyuki; Shigematsu, Hisayuki; Tokumo, Masaki; Sou, Junichi; Asano, Hiroaki; Ichimura, Kouichi; Aoe, Keisuke; Aoe, Motoi; Kiura, Katsuyuki; Shimizu, Kenji; Date, Hiroshi; Shimizu, Nobuyoshi.

In: International Journal of Cancer, Vol. 120, No. 6, 15.03.2007, p. 1239-1247.

Research output: Contribution to journalArticle

Ichihara, S, Toyooka, S, Fujiwara, Y, Hotta, K, Shigematsu, H, Tokumo, M, Sou, J, Asano, H, Ichimura, K, Aoe, K, Aoe, M, Kiura, K, Shimizu, K, Date, H & Shimizu, N 2007, 'The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer', International Journal of Cancer, vol. 120, no. 6, pp. 1239-1247. https://doi.org/10.1002/ijc.22513
Ichihara, Shuji ; Toyooka, Shinichi ; Fujiwara, Yoshiro ; Hotta, Katsuyuki ; Shigematsu, Hisayuki ; Tokumo, Masaki ; Sou, Junichi ; Asano, Hiroaki ; Ichimura, Kouichi ; Aoe, Keisuke ; Aoe, Motoi ; Kiura, Katsuyuki ; Shimizu, Kenji ; Date, Hiroshi ; Shimizu, Nobuyoshi. / The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. In: International Journal of Cancer. 2007 ; Vol. 120, No. 6. pp. 1239-1247.
@article{af306c642d0941d8aa2e0c1ecf4efdda,
title = "The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer",
abstract = "We investigated the relationships between genetic factors and clinical outcome in Japanese non-small-cell lung cancer (NSCLC) patients treated with gefitinib. Ninety-eight NSCLC patients who had been treated with gefitinib, were screened for mutations in epidermal growth factor receptor (EGFR) exons 18-21, KRAS exon2, and polymorphisms including the CA simple sequence repeat in intronl (CA-SSR1) and single nucleotide polymorphisms in the promoter region (-216G/T and -191C/A), using a PCR-based assay and direct sequencing. The EGFR copy number status was also evaluated using a fluorescence in situ hybridization assay. EGFR and KRAS mutations were found in 38 (38.8{\%}) and 8 (8.2{\%}) of the 98 patients, respectively. A high EGFR copy number status was identified in 31 (41.3{\%}) of the 75 assessable patients. Drug-sensitive EGFR mutations limited to exon19 deletions and L858R were independent predictive factors of a stronger sensitivity to gefitinib (p = 0.0002), the overall survival (OS) (p = 0.0036), and prolonged progression-free survival (PFS) (p <0.0001). The EGFR copy number status was not related to a sensitivity to gefitinib and prolonged OS and PFS. Regarding polymorphisms, patients with a short CA-SSR1 showed a prolonged OS as compared with those with a long length in patients with a drug-sensitive EGFR mutation, although this difference was not significant (p = 0.13). Thus, drug-sensitive EGFR mutations predict a favorable clinical outcome and a high EGFR copy number may not be related to clinical benefits in gefitinib-treated Japanese patients with NSCLC. Our findings also suggest that the CA-SSR1 length may influence the clinical outcome in patients with a drug-sensitive EGFR mutation.",
keywords = "Amplification, EGFR, Gefitinib, Mutation, NSCLC, Polymorphism",
author = "Shuji Ichihara and Shinichi Toyooka and Yoshiro Fujiwara and Katsuyuki Hotta and Hisayuki Shigematsu and Masaki Tokumo and Junichi Sou and Hiroaki Asano and Kouichi Ichimura and Keisuke Aoe and Motoi Aoe and Katsuyuki Kiura and Kenji Shimizu and Hiroshi Date and Nobuyoshi Shimizu",
year = "2007",
month = "3",
day = "15",
doi = "10.1002/ijc.22513",
language = "English",
volume = "120",
pages = "1239--1247",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

AU - Ichihara, Shuji

AU - Toyooka, Shinichi

AU - Fujiwara, Yoshiro

AU - Hotta, Katsuyuki

AU - Shigematsu, Hisayuki

AU - Tokumo, Masaki

AU - Sou, Junichi

AU - Asano, Hiroaki

AU - Ichimura, Kouichi

AU - Aoe, Keisuke

AU - Aoe, Motoi

AU - Kiura, Katsuyuki

AU - Shimizu, Kenji

AU - Date, Hiroshi

AU - Shimizu, Nobuyoshi

PY - 2007/3/15

Y1 - 2007/3/15

N2 - We investigated the relationships between genetic factors and clinical outcome in Japanese non-small-cell lung cancer (NSCLC) patients treated with gefitinib. Ninety-eight NSCLC patients who had been treated with gefitinib, were screened for mutations in epidermal growth factor receptor (EGFR) exons 18-21, KRAS exon2, and polymorphisms including the CA simple sequence repeat in intronl (CA-SSR1) and single nucleotide polymorphisms in the promoter region (-216G/T and -191C/A), using a PCR-based assay and direct sequencing. The EGFR copy number status was also evaluated using a fluorescence in situ hybridization assay. EGFR and KRAS mutations were found in 38 (38.8%) and 8 (8.2%) of the 98 patients, respectively. A high EGFR copy number status was identified in 31 (41.3%) of the 75 assessable patients. Drug-sensitive EGFR mutations limited to exon19 deletions and L858R were independent predictive factors of a stronger sensitivity to gefitinib (p = 0.0002), the overall survival (OS) (p = 0.0036), and prolonged progression-free survival (PFS) (p <0.0001). The EGFR copy number status was not related to a sensitivity to gefitinib and prolonged OS and PFS. Regarding polymorphisms, patients with a short CA-SSR1 showed a prolonged OS as compared with those with a long length in patients with a drug-sensitive EGFR mutation, although this difference was not significant (p = 0.13). Thus, drug-sensitive EGFR mutations predict a favorable clinical outcome and a high EGFR copy number may not be related to clinical benefits in gefitinib-treated Japanese patients with NSCLC. Our findings also suggest that the CA-SSR1 length may influence the clinical outcome in patients with a drug-sensitive EGFR mutation.

AB - We investigated the relationships between genetic factors and clinical outcome in Japanese non-small-cell lung cancer (NSCLC) patients treated with gefitinib. Ninety-eight NSCLC patients who had been treated with gefitinib, were screened for mutations in epidermal growth factor receptor (EGFR) exons 18-21, KRAS exon2, and polymorphisms including the CA simple sequence repeat in intronl (CA-SSR1) and single nucleotide polymorphisms in the promoter region (-216G/T and -191C/A), using a PCR-based assay and direct sequencing. The EGFR copy number status was also evaluated using a fluorescence in situ hybridization assay. EGFR and KRAS mutations were found in 38 (38.8%) and 8 (8.2%) of the 98 patients, respectively. A high EGFR copy number status was identified in 31 (41.3%) of the 75 assessable patients. Drug-sensitive EGFR mutations limited to exon19 deletions and L858R were independent predictive factors of a stronger sensitivity to gefitinib (p = 0.0002), the overall survival (OS) (p = 0.0036), and prolonged progression-free survival (PFS) (p <0.0001). The EGFR copy number status was not related to a sensitivity to gefitinib and prolonged OS and PFS. Regarding polymorphisms, patients with a short CA-SSR1 showed a prolonged OS as compared with those with a long length in patients with a drug-sensitive EGFR mutation, although this difference was not significant (p = 0.13). Thus, drug-sensitive EGFR mutations predict a favorable clinical outcome and a high EGFR copy number may not be related to clinical benefits in gefitinib-treated Japanese patients with NSCLC. Our findings also suggest that the CA-SSR1 length may influence the clinical outcome in patients with a drug-sensitive EGFR mutation.

KW - Amplification

KW - EGFR

KW - Gefitinib

KW - Mutation

KW - NSCLC

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=33846994719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846994719&partnerID=8YFLogxK

U2 - 10.1002/ijc.22513

DO - 10.1002/ijc.22513

M3 - Article

C2 - 17192902

AN - SCOPUS:33846994719

VL - 120

SP - 1239

EP - 1247

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -